Top 10 Companies in AI for Cancer Diagnosis Market (2026): Market Leaders Powering Global Oncology

MARKET INSIGHTS

Global AI for Cancer Diagnosis market size was valued at USD 205 million in 2025. The market is projected to grow from USD 279.6 million in 2026 to USD 1716 million by 2034, exhibiting a CAGR of 36.4% during the forecast period.

AI for Cancer Diagnosis refers to the application of machine learning algorithms and deep learning models to analyze medical data for the detection, characterization, and monitoring of cancerous growths. These sophisticated tools process complex datasets such as radiology images (CT, MRI, mammograms), pathology slides, and genomic information to assist clinicians. The primary objective is to enhance diagnostic accuracy, reduce interpretation times, and enable earlier detection of cancers, which is critical for improving patient outcomes.

This market is experiencing explosive growth, primarily driven by the rising global incidence of cancer and a significant shortage of specialized oncologists and radiologists. Furthermore, advancements in computing power and the availability of large, annotated medical datasets for training algorithms are accelerating development. Key players like Lunit Inc., Infervision, and Ibex Medical Analytics are at the forefront, securing regulatory approvals for their AI‑powered solutions that analyze breast, lung, and prostate cancers. The integration of these tools into hospital and clinic workflows is becoming increasingly common, signaling a major shift towards data‑driven precision oncology.

AI for Cancer Diagnosis Market – View in Detailed Research Report

Top 10 Companies in AI for Cancer Diagnosis Market (2026)

1. Lunit Inc. (South Korea)

   Headquarters: Seoul, South Korea
   Key Offering: AI‑powered diagnostic software for mammography and chest X‑ray analysis

   Lunit’s platform delivers automated detection of breast and lung lesions, leveraging convolutional neural networks trained on millions of annotated images. The system integrates seamlessly with PACS, providing real‑time risk scores that help radiologists prioritize cases and reduce diagnostic workload.

   Sustainability & Growth Initiatives: Focus on expanding to emerging markets and collaborating with global health institutions to standardize AI‑based screening protocols.

   • FDA clearance for breast cancer screening in 2022.
   • Partnership with leading oncology centers in the United States.
   • Investment in multi‑modal AI to incorporate genomic data.

2. Infervision (China)

   Headquarters: Beijing, China
   Key Offering: AI solutions for lung, breast, and colorectal cancer detection

   Infervision’s flagship product, AI‑CXR, delivers rapid analysis of chest radiographs, achieving sensitivity comparable to expert radiologists. The company has secured CE marking and is expanding its presence in Southeast Asia.

   Sustainability & Growth Initiatives: Scaling cloud‑based analytics to support tele‑oncology services in rural regions.

   • CE approval for lung cancer screening in 2021.
   • Collaboration with Chinese national health programs.
   • Development of a portable AI‑enabled chest X‑ray device.

3. Ibex Medical Analytics (Israel)

   Headquarters: Tel Aviv, Israel
   Key Offering: Pathology decision‑support platform for prostate cancer

   Ibex’s PathAI system interprets histopathology slides, identifying aggressive tumor phenotypes with high precision. The platform’s ability to flag high‑risk lesions supports urologists in selecting patients for early intervention.

   Sustainability & Growth Initiatives: Expanding AI models to other cancer types and integrating with electronic health records.

   • FDA clearance for prostate cancer diagnostics in 2023.
   • Partnership with major U.S. cancer centers.
   • Investment in federated learning to preserve patient privacy.

4. Oncora Medical (United States)

   Headquarters: San Francisco, California
   Key Offering: Oncology data management and clinical decision‑support platform

   Oncora’s platform aggregates patient data across modalities, applying predictive analytics to recommend personalized treatment pathways. The solution is adopted by academic medical centers to streamline clinical trials.

   Sustainability & Growth Initiatives: Focus on integrating AI with drug discovery pipelines.

   • Partnership with leading pharmaceutical companies.
   • Expansion into European markets through joint ventures.
   • Investment in secure data sharing frameworks.

5. Niramai Health Analytix (India)

   Headquarters: Bangalore, India
   Key Offering: Thermal imaging‑based breast cancer screening solution

   Niramai’s non‑invasive platform captures heat signatures to detect malignant tissue, offering a radiation‑free alternative to mammography. The technology is especially valuable in low‑resource settings.

   Sustainability & Growth Initiatives: Scaling to remote clinics and integrating with national screening programs.

   • FDA clearance for breast cancer screening in 2022.
   • Collaboration with Indian public health ministries.
   • Development of a portable handheld device.

6. Kheiron Medical (United Kingdom)

   Headquarters: London, United Kingdom
   Key Offering: AI‑based breast cancer screening software

   Kheiron’s AI system analyzes mammograms to flag suspicious lesions, reducing false‑positive rates and improving early detection. The company has secured CE marking and is expanding into EU markets.

   Sustainability & Growth Initiatives: Focusing on cost‑effective solutions for public health systems.

   • CE approval for breast cancer screening in 2021.
   • Partnerships with NHS trusts.
   • Investment in open‑source AI models for transparency.

7. Shukun Technology (China)

   Headquarters: Shanghai, China
   Key Offering: AI‑enhanced imaging analytics for multiple cancer types

   Shukun’s platform provides automated segmentation and lesion characterization across CT, MRI, and PET scans. The company emphasizes real‑time analytics for surgical planning.

   Sustainability & Growth Initiatives: Integration with China’s national AI health strategy.

   • Partnership with major Chinese hospitals.
   • Development of cloud‑based AI services.
   • Focus on data privacy compliance.

8. Imagene AI (Israel)

   Headquarters: Tel Aviv, Israel
   Key Offering: AI platform for radiology and pathology image analysis

   Imagene’s platform delivers high‑accuracy detection of lung, breast, and colorectal cancers, with a user interface designed for seamless integration into clinical workflows.

   Sustainability & Growth Initiatives: Expanding AI models to include multi‑modal data fusion.

   • CE approval for lung cancer screening in 2020.
   • Collaboration with European health agencies.
   • Investment in AI‑driven triage systems.

9. Therapixel (France)

   Headquarters: Paris, France
   Key Offering: AI‑enabled pathology analysis for breast and prostate cancers

   Therapixel’s solution uses deep learning to analyze histopathology slides, providing quantitative metrics that guide treatment decisions. The platform is adopted by pathology labs across Europe.

   Sustainability & Growth Initiatives: Focus on interoperability with laboratory information systems.

   • CE clearance for breast cancer diagnostics in 2022.
   • Partnerships with leading European pathology centers.
   • Investment in explainable AI features.

10. Enlitic (United States)

    Headquarters: San Diego, California
    Key Offering: AI‑driven medical imaging analysis for oncology

    Enlitic’s platform applies convolutional neural networks to CT, MRI, and PET scans, delivering automated lesion detection and risk stratification. The company emphasizes rapid deployment in clinical settings.

    Sustainability & Growth Initiatives: Expanding into international markets and integrating with oncology data platforms.

    • FDA clearance for lung cancer screening in 2021.
    • Collaboration with global oncology networks.
    • Investment in AI‑powered predictive analytics.

Download FREE Sample Report

AI for Cancer Diagnosis Market – View in Detailed Research Report

Outlook

As AI tools become more entrenched in diagnostic pathways, adoption is expected to accelerate in both developed and emerging markets. The convergence of cloud infrastructure, standardized data sets, and regulatory clarity is creating an environment where hospitals can deploy AI solutions with confidence. Over the next decade, the focus will shift from proof‑of‑concept deployments to robust, evidence‑based integration that delivers measurable improvements in patient outcomes.

Future Trends

Key developments include the synthesis of multi‑modal data—combining imaging, pathology, and genomics—to provide a holistic view of tumor biology. This approach will enable predictive models that anticipate treatment response and guide personalized therapy. Additionally, the move towards real‑time decision support embedded within PACS and electronic health records will streamline workflows, reduce turnaround times, and lower the barrier to clinician adoption. Finally, advances in federated learning and privacy‑preserving analytics will address data security concerns, allowing institutions to collaborate on model improvement without compromising patient confidentiality.